

Frexalimab

Cat. No.:	HY-P99625
CAS No.:	2515463-86-0
Target:	TNF Receptor
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β -cell destruction. Frexalimab is promising for multiple sclerosis, lupus erythematosus, Sjögren's syndrome and type I diabetes research ^{[1][2][3][4][5]} .
In Vitro	Frexalimab is a second-generation anti-CD40L humanized IgG1 monoclonal antibody that has been Fc-engineered. The Fc engineering abrogates the platelet activation that is triggered by Fc γ RIIa stimulation by immune complexes ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Bruce A C Cree, et al. New drugs for multiple sclerosis: new treatment algorithms. *Curr Opin Neurol*. 2022 Jun 1;35(3):262-270.
- [2]. Vermersch P, et al. Inhibition of CD40L with Frexalimab in Multiple Sclerosis. *N Engl J Med*. 2024 Feb 15;390(7):589-600.
- [3]. Carvalho T. Anti-CD40L antibody frexalimab slows new brain lesions in multiple sclerosis. *Nat Med*. 2023 Aug;29(8):1882-1883.
- [4]. Weiskorn J, et al. Moving from Insulin Substitution to the Treatment of the Underlying Autoimmune Disease in Type 1 Diabetes. *Horm Res Paediatr*. 2024 Apr 30:1-8.
- [5]. Maddaloni E, et al. Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes. *Expert Opin Investig Drugs*. 2024 Apr;33(4):303-318.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA